R
Richuan Zheng
Researcher at Janssen Pharmaceutica
Publications - 6
Citations - 236
Richuan Zheng is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Placebo & Dermatology Life Quality Index. The author has an hindex of 4, co-authored 5 publications receiving 137 citations.
Papers
More filters
Journal ArticleDOI
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
TL;DR: Guselkumab treatment demonstrated efficacy and showed no safety concerns in Japanese patients with GPP and EP through week 52 and consistently showed improvement in responses of secondary end‐points such as Psoriasis Area and Severity Index, Investigator's Global Assessment, Japanese Dermatological Association severity index and improvement in body surface area involvement.
Journal ArticleDOI
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
TL;DR: In conclusion, guselkumab treatment demonstrated superior efficacy over placebo and was well tolerated in Japanese patients with moderate to severe plaque‐type psoriasis.
Journal ArticleDOI
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Tadashi Terui,Satomi Kobayashi,Yukari Okubo,Masamoto Murakami,Richuan Zheng,Hitomi Morishima,Ryosuke Goto,Takayuki Kimura +7 more
TL;DR: Efficacy end points improved consistently through week 52, and health-related quality of life also improved significantly, meaning Guselkumab may be an effective and safe treatment option for management of palmoplantar pustulosis.
Journal ArticleDOI
Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
Toshiyuki Yamamoto,Kunihiko Fukuda,Akimichi Morita,Takayuki Kimura,Hitomi Morishima,Ryosuke Goto,Richuan Zheng,Tadashi Terui +7 more
TL;DR: Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psOriasis, erythrodermic Psoriasis and palmoplantar pustulosis.
Journal ArticleDOI
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.
TL;DR: The safety and efficacy of guselkumab for palmoplantar pustulosis (PPP) have been established through week (W)52; however, no sufficient information is available beyond 1 year.